Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects

European Journal of Clinical Pharmacology

Volumn 64, Issue 10, 2008, Pages 961-966

  Almeida, Luis ^a   Falcão, Amílcar ^b   Vaz Da Silva, Manuel ^a   Nunes, Teresa ^a   Santos, Ana Teresa ^a   Rocha, José Francisco ^a   Neta, Carla ^c   Macedo, Tice ^c   Fontes Ribeiro, C ^c   Soares Da Silva, P ^a  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b 4Health Limited   (Portugal)

^c ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

Author keywords

Coagulation; Drug interaction; Nebicapone; Pharmacokinetics; Warfarin

Indexed keywords

1 (3,4 DIHYDROXY 5 NITROPHENYL) 2 PHENYLETHANONE; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; NEBICAPONE; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; ECCHYMOSIS; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; POLLAKISURIA; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; SINGLE DRUG DOSE; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTICOAGULANTS; AREA UNDER CURVE; BLOOD COAGULATION; CATECHOL O-METHYLTRANSFERASE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; METABOLIC CLEARANCE RATE; STEREOISOMERISM; THERAPEUTIC EQUIVALENCY; WARFARIN; YOUNG ADULT;

EID: 53249083947     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0534-2     Document Type: Article

References (16)

1. L Almeida P Soares-da-Silva 2003 Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects J Clin Pharmacol 43 1350 1360
2. J Ferreira L Almeida L Cunha M Ticmeanu MM Rosa C Januário C-E Mitu M Coelho L Correia-Guedes A Morgadinho T Nunes LC Wright A Falcão C Sampaio P Soares-da-Silva 2008 Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase (COMT) activity and motor fluctuations in patients with Parkinson's disease Clin Neuropharmacol 31 2 18
3. L Almeida M Vaz-da-Silva P Silveira A Falcao J Maia A Loureiro L Torrao R Machado L Wright P Soares-da-Silva 2004 Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa Clin Neuropharmacol 27 17 24
4. P Silveira M Vaz-Da-Silva L Almeida J Maia A Falcao A Loureiro L Torrao R Machado L Wright P Soares-Da-Silva 2003 Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide Eur J Clin Pharmacol 59 603 609
5. J Ansell J Hirsh J Dalen 2001 Managing oral anticoagulant therapy Chest 119 22S 38S
6. DJ Greenblatt LL von Moltke 2005 Interaction of warfarin with drugs, natural substances, and foods J Clin Pharmacol 45 127 132
7. A Yacobi JA Udall G Levy 1976 Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect Clin Pharmacol Ther 19 552 558
8. S Harder P Thurmann 1996 Clinically important drug interactions with anticoagulants. An update Clin Pharmacokinet 30 416 444
9. JS Cropp HI Bussey 1997 A review of enzyme induction of warfarin metabolism with recommendations for patient management Pharmacotherapy 17 917 928
10. PN Patsalos JS Duncan 1993 Antiepileptic drugs. A review of clinically significant drug interactions Drug Safety 9 156 184
11. Data on file. BIAL - Portela & Ca, SA
12. PR Ring JM Bostick 2000 Validation of a method for the determination of R-warfarin and S-warfarin in human plasma using LC with UV detection J Pharm Biomed Anal 22 573 581
13. DR Mungall TM Ludden J Marshall 1985 Pharmacokinetics of racemic warfarin in adult patients J Pharmacokinet Biopharm 13 213 227
14. VW Steinijans R Sauter D Hauschke 1995 Reference tables for the intra-subject coefficient of variation in bioequivalence studies Int J Clin Pharmacol Ther 33 427 430
15. EMEA/Committee for Proprietary Medicinal Products (CPMP) (2001) Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/1401/98. The European Agency for the Evaluation of Medicinal Products, London
16. L Torrão J Costa T Nunes R Machado E Soares J Maia A Falcão M Vaz-da-Silva L Wright L Almeida P Soares-da-Silva 2007 Effect of nebicapone (BIA 3-202) 100 mg, 200 mg and 300 mg administered at 4-h intervals on the erythrocyte soluble catechol-O-methyltransferase (S-COMT) activity in healthy subjects Br J Clin Pharmacol 63 783 784